{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:50:08Z","timestamp":1793213408409,"version":"4.5.0"},"reference-count":96,"publisher":"Informa UK Limited","issue":"21","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019799","name":"G1 Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019799","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.2217\/fon-2023-0513","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T09:01:41Z","timestamp":1712566901000},"page":"1515-1530","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":90,"title":["The impact of myelosuppression on quality of life of patients treated with chemotherapy"],"prefix":"10.1080","volume":"20","author":[{"given":"Jeffrey","family":"Crawford","sequence":"first","affiliation":[{"name":"Duke Cancer Institute, Duke Medicine, Durham, NC 27710, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Herndon","sequence":"additional","affiliation":[{"name":"Cone Health Cancer Center, Greensboro, NC 27403, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Gmitter","sequence":"additional","affiliation":[{"name":"Patient Author, Chapel Hill, NC 27516, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Weiss","sequence":"additional","affiliation":[{"name":"UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01419-6"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.2020570"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190014546108"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2006.0056"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04875-1"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.200"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw325"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy323"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02142"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.1734"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.06.010"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/tme.12439"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S88110"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103193"},{"key":"e_1_3_6_18_1","unstructured":"United States Food and Drug Administration. EPOGEN\u00ae (epoetin alfa) injection for intravenous or subcutaneous use [prescribing information]. Thousand Oaks (CA): Amgen Inc.; July 2018 [cited 2024 Feb 16]. Available from: www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Epogen\/epogen_pi_hcp_english.pdf"},{"key":"e_1_3_6_19_1","unstructured":"United States Food and Drug Administration. COSELA\u00ae (trilaciclib) for injection for intravenous use [prescribing information]. Durham (NC): G1 Therapeutics Inc.; August 2023 [cited 2024 Feb 16]. Available from: www.g1therapeutics.com\/file.cfm\/69\/docs\/cosela_approved_label_8-3-2023.pdf"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0775"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aal3986"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33453"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01538-0"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz278"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.03.010"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4089"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.533"},{"key":"#cr-split#-e_1_3_6_28_1.1","unstructured":"BeyondSpring Pharmaceuticals Inc. BeyondSpring receives breakthrough therapy designations from both US FDA and China NMPA for plinabulin in chemotherapy-induced neutropenia indication Florham Park (NJ): BeyondSpring Pharmaceuticals Inc. [updated 2020 Sep 8"},{"key":"#cr-split#-e_1_3_6_28_1.2","unstructured":"cited 2024 Feb 16]. Available from: https:\/\/beyondspringpharma.com\/beyondspring-receives-breakthrough-therapy-designations-from-both-u-s-fda-and-china-nmpa-for-plinabulin-in-chemotherapy-induced-neutropenia-indication\/"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45446"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9091"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab057"},{"key":"#cr-split#-e_1_3_6_32_1.1","unstructured":"FibroGen Inc. FibroGen receives complete response letter from the FDA for roxadustat for anemia of chronic kidney disease San Francisco (CA): FibroGen Inc. [updated 2021 Aug 11"},{"key":"#cr-split#-e_1_3_6_32_1.2","unstructured":"cited 2024 Feb 16]. Available from: https:\/\/investor.fibrogen.com\/news-releases\/news-release-details\/fibrogen-receives-complete-response-letter-fda-roxadustat-anemia"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26865"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01931"},{"key":"e_1_3_6_35_1","unstructured":"United States Food and Drug Administration. NPLATE\u00ae (romiplostim) for injection for subcutaneous use [prescribing information]. Thousand Oaks (CA): Amgen Inc.; February 2022 [cited 2024 Feb 16]. Available from: www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Nplate\/nplate_pi_hcp_english.pdf"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.251900"},{"key":"e_1_3_6_37_1","unstructured":"National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Hematopoietic Growth Factors Version 3.2024. \u00a9 National Comprehensive Cancer Network Inc. 2024. All rights reserved. Accessed February 16 2024. To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application and disclaims any responsibility for their application or use in any way."},{"key":"e_1_3_6_38_1","unstructured":"United States Food and Drug Administration. DOPTELET\u00ae (avatrombopag) tablets for oral use [prescribing information]. Durham (NC): AkaRx Inc.; July 2021 [cited 2024 Feb 16]. Available from: https:\/\/doptelet.com\/themes\/pdf\/prescribing-information.pdf"},{"key":"#cr-split#-e_1_3_6_39_1.1","unstructured":"Sobi. FDA grants avatrombopag orphan drug designation for the treatment of chemotherapy-induced thrombocytopenia. Stockholm Sweden: Swedish Orphan Biovitrum AB. [updated 2019 Dec 21"},{"key":"#cr-split#-e_1_3_6_39_1.2","unstructured":"cited 2024 Feb 16]. Available from: www.sobi.com\/en\/press-releases\/fda-grants-avatrombopag-orphan-drug-designation-treatment-chemotherapy-induced"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00001-1"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279512"},{"key":"#cr-split#-e_1_3_6_42_1.1","unstructured":"National Institutes of Health National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Washington (DC): United States Department of Health and Human Services. [updated 2017 Nov 27"},{"key":"#cr-split#-e_1_3_6_42_1.2","unstructured":"cited 2024 Feb 16]. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100466"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2016.1140052"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6955-4-4"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJCTM.S187569"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2008.0036"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758834014534515"},{"key":"e_1_3_6_49_1","unstructured":"Cancer.Net. Low platelet count or thrombocytopenia. Alexandria (VI): American Society of Clinical Oncology (ASCO); c2005-2024. [updated 2020 Aug; cited 2024 Feb 16]. Available from: www.cancer.net\/coping-with-cancer\/physical-emotional-and-social-effects-cancer\/managing-physical-side-effects\/low-platelet-count-or-thrombocytopenia"},{"key":"e_1_3_6_50_1","unstructured":"FACIT.org. FACIT Measures & Languages. Ponte Vedra Beach (FL): FACIT.org; c2001. [updated 2021; cited 2024 Feb 16]. Available from: www.facit.org\/measures-language-availability"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2008.12.007"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.12.006"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.10.013"},{"key":"e_1_3_6_54_1","first-page":"275b","article-title":"Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN) [abstract 2920]","volume":"21","author":"Okon T","year":"2002","unstructured":"Okon T, Fortner B, Schwartzberg L et al. Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN) [abstract 2920]. Proc. Am. Soc. Clin. Oncol. 2002;21:275b.","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S292462"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1492151"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-007-0270-7"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2016.03.016"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2014.07.011"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07103-5"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt226"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2013.08.006"},{"key":"e_1_3_6_63_1","unstructured":"Macmillan Cancer Support. G-CSF (granulocyte-colony stimulating factor). London United Kingdom: Macmillan Cancer Support; c2024. [updated 2024; cited 2024 Feb 16]. Available from: www.macmillan.org.uk\/cancer-information-and-support\/treatments-and-drugs\/g-csf"},{"key":"e_1_3_6_64_1","unstructured":"United States Food and Drug Administration. NEULASTA\u00ae (pegfilgrastim) injection [patient information]. Thousand Oaks (CA): Amgen Inc.; January 2021 [cited 2024 Feb 16]. Available from: www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Neulasta\/neulasta_ppi_pt_english.pdf"},{"key":"e_1_3_6_65_1","unstructured":"United States Food and Drug Administration. ROLVEDON\u2122 (eflapegrastim-xnst) injection for subcutaneous use [prescribing information]. Irvine (CA): Spectrum Pharmaceuticals Inc.; June 2023 [cited 2024 Feb 16]. Available from: www.rolvedon.com\/pdf\/rolvedon-prescribing-information.pdf"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000952"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0715"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00623"},{"key":"#cr-split#-e_1_3_6_69_1.1","unstructured":"OncLive\u00ae. Aileron terminates Phase Ib trial evaluating ALRN-6924 in P53-mutant breast cancer. Cranbury (NJ): MJH Life Sciences. [updated 2023 Feb 22"},{"key":"#cr-split#-e_1_3_6_69_1.2","unstructured":"cited 2024 Feb 16]. Available from: www.onclive.com\/view\/aileron-terminates-phase-1b-trial-evaluating-alrn-6924-in-p53-mutant-breast-cancer"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.03.008"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05336-w"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(15)30388-9"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00394.x"},{"key":"e_1_3_6_74_1","unstructured":"LIVESTRONG \u201cI learned to live with it\u201d is not good enough: Challenges reported by post-treatment cancer survivors in the LIVESTRONG surveys. A LIVESTRONG report 2010 Austin (TX): The Livestrong Foundation. [updated 2011; cited 2024 Feb 16]. Available from: https:\/\/www.livestrong.org\/sites\/default\/files\/what-we-do\/reports\/lssurvivorsurveyreport_final_0.pdf"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103248"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-0971-1"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10763"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh235"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2865"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.10.014"},{"issue":"5","key":"e_1_3_6_81_1","first-page":"2325","article-title":"Impact of epoetin-beta on anemia and health-related quality of life in cancer patients: a prospective observational study using the generic 15D instrument","volume":"34","author":"M\u00e4enp\u00e4\u00e4 J","year":"2014","unstructured":"M\u00e4enp\u00e4\u00e4 J, Puistola U, Riska H et al. Impact of epoetin-beta on anemia and health-related quality of life in cancer patients: a prospective observational study using the generic 15D instrument. Anticancer Res. 2014;34(5):2325\u20132329.","journal-title":"Anticancer Res."},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0279"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22221"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22943"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5202"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32917"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-01017-z"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5354-5"},{"issue":"4","key":"e_1_3_6_89_1","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter DJ","year":"2015","unstructured":"Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park) 2015;29(4):282\u2013294.","journal-title":"Oncology (Williston Park)"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-006-0102-1"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1589"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1159\/000151350"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07464.x"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0513","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T08:24:07Z","timestamp":1727339047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":96,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024,7,2]]}},"alternative-id":["10.2217\/fon-2023-0513"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0513","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}